Head-to-head evidence
Proventil vs Salbutamol HFA-134a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Proventil
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00577655 · Phase 3 · completed
The trial randomized 103 children to albuterol or placebo and masked participants, caregivers, investigators, and outcome assessors. Its primary measures were physiologic lung-function outcomes rather than hard clinical outcomes; the FEV1 comparison was statistically significant, while the PEF comparison was not significant at the prespecified threshold, so the findings were mixed.
Salbutamol HFA-134a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The study randomized 477 adults and used quadruple blinding with an active salbutamol comparator. Its primary endpoint was the number of participants with adverse events, but no results or statistical comparison are posted, so the outcome is currently unknown.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Proventil's landscape · Salbutamol HFA-134a's landscape